Display Settings:

Format
Items per page

Send to:

Choose Destination

Results: 20

1.

vanadium pentoxide

MedGen UID:
43077
Concept ID:
C0084943
Pharmacologic Substance
2.

Fibrosis of lung

Pulmonary fibrosis harms the tissues deep in your lungs. The air sacs in your lungs and their supporting structures become scarred and make your lungs thick and stiff. That makes it hard for you to catch your breath, and your blood may not get enough oxygen. One cause of pulmonary fibrosis is interstitial lung disease. Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. Pulmonary fibrosis is also associated with some connective tissue diseases. It can be a side effect of a medicine. Sometimes no one knows the cause of the disease. Smoking can boost your risk or make your illness worse.  [from MedlinePlus]

MedGen UID:
11028
Concept ID:
C0034069
Disease or Syndrome
3.

Necrosis

A permanent cessation of all vital functions of a tissue. [GOC:dph] [from GO]

MedGen UID:
10199
Concept ID:
C0027540
Pathologic Function
4.

Inflammation

A microscopic finding indicating the presence of acute, subacute or chronic inflammation in a tissue sample. [from NCI]

MedGen UID:
7072
Concept ID:
C0021368
Pathologic Function
5.

Fibrosis

The formation of fibrous tissue; fibroid or fibrous degeneration. [from NCI]

MedGen UID:
5179
Concept ID:
C0016059
Pathologic Function
6.

Pulmonary fibrosis

Replacement of normal lung tissues are progressively replaced by fibroblasts and collagen. [from HPO]

MedGen UID:
505156
Concept ID:
CN002000
Finding
7.

Idiopathic fibrosing alveolitis, chronic form

Familial pulmonary fibrosis (FPF in this GeneReview) is defined as idiopathic interstitial pneumonia (IIP) in two or more first-degree relatives (parent, sib, or offspring). The clinical findings of IIP are bibasilar reticular abnormalities, ground glass opacities, or diffuse nodular lesions on high-resolution computed tomography and abnormal pulmonary function studies that include evidence of restriction (reduced VC with an increase in FEV1/FVC ratio) and/or impaired gas exchange (increased P(A-a)O2 with rest or exercise or decreased diffusion capacity of the lung for carbon monoxide). FPF usually presents between ages 50 and 70 years. FPF may be complicated by lung cancer; bronchoalveolar cell carcinoma, small-cell carcinoma, and adenocarcinoma have been described. [from GeneReviews]

MedGen UID:
321462
Concept ID:
C1800706
Disease or Syndrome
8.

Severe

A term used to describe cells that look abnormal under a microscope. These cells are more likely to grow and spread quickly than cells in low-grade cancer or in growths that may become cancer. [from NCI]

MedGen UID:
104640
Concept ID:
C0205082
9.

Mediator brand of benfluorex hydrochloride

An agent that acts as a link between parties, objects, or actions. [from NCI]

MedGen UID:
93010
Concept ID:
C0127400
Pharmacologic Substance
10.

Oncolysis

The lysis (breakdown) of cancer cells. This can be caused by chemical or physical means (for example, strong detergents or high-energy sound waves) or by infection with a strain of virus that can lyse cells. [from NCI]

MedGen UID:
90709
Concept ID:
C0333516
Neoplastic Process
11.

Prostaglandins

One of several hormone-like substances made by the body. Different PGs control blood pressure, contraction of smooth muscles, and other processes within tissues where they are made. Certain PGs are being studied as cancer biomarkers. [from NCI]

MedGen UID:
18692
Concept ID:
C0033554
Pharmacologic Substance
12.

Prostenon

MedGen UID:
152085
Concept ID:
C0699578
Pharmacologic Substance
13.

Genetic predisposition

A latent susceptibility to disease at the genetic level, which may be activated under certain conditions. [from MeSH]

MedGen UID:
137259
Concept ID:
C0314657
14.

Mediator of inflammation

The endogenous compounds that mediate inflammation (AUTACOIDS) and related exogenous compounds including the synthetic prostaglandins (PROSTAGLANDINS, SYNTHETIC). [from MeSH]

MedGen UID:
66209
Concept ID:
C0243042
Pharmacologic Substance
15.

Hamman-Rich syndrome

MedGen UID:
39340
Concept ID:
C0085786
Disease or Syndrome
16.

Respiratory Tract Diseases

MedGen UID:
19750
Concept ID:
C0035242
Disease or Syndrome
17.

Up-Regulation (Physiology)

A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. [from MeSH]

MedGen UID:
12003
Concept ID:
C0041904
Molecular Function
18.

Disorder of lung

When you breathe, your lungs take in oxygen from the air and deliver it to the bloodstream. The cells in your body need oxygen to work and grow. During a normal day, you breathe nearly 25,000 times. People with lung disease have difficulty breathing. Millions of people in the U.S. have lung disease. If all types of lung disease are lumped together, it is the number three killer in the United States. The term lung disease refers to many disorders affecting the lungs, such as asthma, chronic obstructive pulmonary disease, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure. Dept. of Health and Human Services Office on Women's Health.  [from MedlinePlus]

MedGen UID:
7399
Concept ID:
C0024115
Disease or Syndrome
19.

Dinoprostone

The most common and most biologically active of the mammalian prostaglandins. It exhibits most biological activities characteristic of prostaglandins and has been used extensively as an oxytocic agent. The compound also displays a protective effect on the intestinal mucosa. [from MeSH]

MedGen UID:
3843
Concept ID:
C0012472
Pharmacologic Substance
20.

Prostaglandin-endoperoxide synthase deficiency

Platelet prostaglandin-endoperoxidase synthase-1 deficiency is a hematologic disorder characterized by mildly increased bleeding due to a platelet defect. The PTGS1 gene (176805) encodes prostaglandin-endoperoxidase synthase-1, also known as COX1 or PGHS1, which catalyzes the formation of prostaglandin G2 (PGG2) and prostaglandin H2 from arachidonic acid, and the downstream formation of thromboxane A2 (TXA2) and prostacyclin. Thromboxane A2 is important for platelet aggregation (summary by Matijevic-Aleksic et al., 1996). [from OMIM]

MedGen UID:
414043
Concept ID:
C2751535
Disease or Syndrome

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...